Medindia

X

MD Anderson Becomes a GeneGo Center of Excellence Using MetaCore for Oncology Research

Tuesday, September 2, 2008 General News J E 4
Advertisement
ST. JOSEPH, Mich., Sept. 2 GeneGo, Inc., the leadingsystems biology tools company, announced today that MD Anderson has become acertified GeneGo Center of Excellence. MD Anderson researchers will haveinstitution-wide access to GeneGo's MetaCore data analysis suite, training andadvanced support. MD Anderson specializes in cancer treatment and researchand is well known for its advanced clinical trials programs. MetaCore will beused throughout many research programs both as a central data repository,management and collaboration platform for clinical OMICs data and as anintegrative pathway analysis suite.

Mary E. Edgerton, a pathologist performing cancer research at MD Andersonand a long-term client, says "I have been using MetaCore for many years in myresearch into pathways and networks that control aggressive behavior incancers. I am currently using it to infer networks from analysis of geneexpression array data for pathways in lung, brain, and breast cancer. I alsouse the curated pathways to formulate mathematical models of molecularnetworks that predict tumor behavior using multiscale modeling. Not only do Ifind the product to be very useful, but I also appreciate the responsivenessof the staff at GeneGo to my technical questions and suggestions. "

"MD Anderson is renowned for their pioneering work in oncology. I haveknown some of the MD's there for a while and I admire their dedication totheir patients and to working hard to find cures," said Julie Bryant, GeneGo'sVP of Business development. "We are proud to have them as an institutioncustomer and a Center of Excellence. We have a large development program inthe area of cancer system biology tools supported by NCI and we are glad tosee this work appreciated by some of the best oncology professionals in theworld working at MD Anderson."

About GeneGo, Inc.

GeneGo, Inc. develops systems biology technology such as compound basedpathway analysis, cheminformatics & bioinformatics software for life scienceresearch. The original computational MetaDiscovery(TM) platform allows anintegration and expert analysis of different kinds of experimental data (mRNAexpression, proteomics, metabolomics, microRNA assays and other phenotypicdata) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics)within the framework of curated biological pathways and networks. GeneGo'sflagship product, MetaCore 5.0(TM), assists pharmaceutical scientists in theareas of target selection and validation, data mining in biology,identification of biomarkers for disease states and toxicology. The secondproduct, MetaDrug 5.0(TM) is designed for prediction of human metabolism,toxicity and biological effects for novel small molecules compounds.MetaBase(TM) represents the knowledge base for MetaCore.

For more information, please visit the company's web site athttp://www.genego.com.

SOURCE GeneGo, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Haemacure Provides Update on Fibrin Sealant Projec...
S
clickNsettle.com, Inc. and Cardo Medical, LLC Anno...